Cardiology

Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.

Ahmad Masri, MD, MS, highlights HCM agents to watch in 2027, including sotagliflozin and EDG-7500, and how MAPLE-HCM challenged beta-blocker use.

Ahmad Masri, MD, MS, discusses the move toward medical therapy in HCM, the nonobstructive treatment gap, and imaging's role in diagnosis and follow-up.

Low-frequency cannabis use was linked to 23% higher odds of self-reported cardiovascular disease and 40% higher odds of stroke in a BRFSS analysis.

Compared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.

Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease (HR, 1.02).

Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.

In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.

John Cleland, MD, PhD, discusses the results of the HF-TRACK study and the potential for the Heartfelt device to improve HF outcomes among monitored patients.

Rami Kahwash discusses his presentation at HFSA 2026, which highlighted the real-world efficacy of cardiac contractility modulation therapy.

Hugh Gallagher, MBBS, PhD, discusses a 27% lower point estimate for cardiovascular events with aspirin that was not significant.

Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.

The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.

Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D.

Fabiano Cavalcante, MD, discusses his secondary analysis of the DISTAL trial, which revealed minimal association between IVT and the effect of EVT in MDVO strokes.

Amy Yu, MD, MSc, discusses her presentation at WSC 2026 discussing highlighting the present danger of this underrepresented disease state.

A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.

A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.

Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.

A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Samantha Pettigrew, MD, reviews HI-PEITHO, PRAGUE-26, and PEERLESS and how they shape intervention choices in intermediate-risk PE at CHEST 2026.

Anjali Vaidya, MD, explains why echocardiography should inform right heart catheterization interpretation in pulmonary hypertension at CHEST 2026.

Participants described how they use risk assessment, payer requirements, and patient preference to sequence PAH therapies.

Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.